FDA Exclusivity View Blocking Opioid Treatment, Suit Says
The U.S. Food and Drug Administration's overbroad exclusivity for an Indivior Inc. drug that treats opioid addiction is blocking a Braeburn Inc. drug that would further expand treatment, Braeburn said in...To view the full article, register now.
Already a subscriber? Click here to view full article